<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
    <meta content="telephone=no" name="format-detection">
    <meta name="viewport" content="width=device-width,initial-scale=1.0">
    <link href="style/css/https://fonts.googleapis.com/css?family=Lato:300,300i,400,400i,700,700i" rel="stylesheet">
    <link href="style/css/main.css" rel="stylesheet">
    <link rel="shortcut icon" href="img/favicon.ico">
    <script src="//ajax.googleapis.com/ajax/libs/jquery/3.1.1/jquery.min.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.9.4/umd/popper.min.js"></script>
    <script src="js/vendor/bootstrap.min.js"></script>
    <script src="js/front-end/getVisibleHeight.js"></script>
    <script src="js/front-end/notifyMainToggle.js"></script>
    <script src="js/front-end/stickyHeader.js"></script>
    <script src="js/front-end/searchToggle.js"></script>
    <script src="js/front-end/notifyTray.js"></script>
    <script src="js/front-end/headerMainNavMainToggle.js"></script>
    <script src="js/front-end/navMainSubToggleMobile.js"></script>
    <script src="js/front-end/swapBackground.js"></script>
    <script src="js/front-end/navMainSubColumns.js"></script>
    <script src="js/front-end/tabs.js"></script>
    <script src="js/front-end/retach.js"></script>
    <script src="js/front-end/internalLinkScrollEffect.js"></script>
    <script src="js/front-end/blurBox.js"></script>
    <script src="https://use.fontawesome.com/3942864d90.js"></script>
    <title>Patient Profiles</title>
  </head>
  <body>
    <form>
      <div class="pageWrap">
        <div class="notifyMain">
          <div class="notifyMain-inner">
            <div class="notifyMain-content">
              <h2 class="notifyMain-heading">Indication and Limitation of use</h2>
              <div class="notifyMain-copy">
                <p><span>Vectibix<sup>&reg; </sup>is indicated for the treatment of patients with wild-type <em>RAS </em>(defined as wild-type in both <em>KRAS </em>and <em>NRAS </em>
                    <as>determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC): </as></span><span>as first-line therapy in combination with FOLFOX, and as monotherapy following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy. </span></p>
                <p>Limitation of Use: Vectibix<sup>&reg; </sup>is not indicated for the treatment of patients with <em>RAS</em>‑mutant mCRC or for whom <em>RAS</em> mutation status is unknown.</p>
              </div>
            </div>
            <div class="notifyMain-close"></div>
          </div>
        </div>
        <div id="pageTop"></div>
        <header class="headerMain">
          <div class="headerMain-util">
            <div class="headerMain-utilInner">
              <ul class="headerMain-navUtil">
                <li class="headerMain-navUtilItem"><a class="headerMain-navUtilLink" href="#safteyInformation">Important Safety Information</a></li>
                <li class="headerMain-navUtilItem"><a class="headerMain-navUtilLink openNotifyMain" href="">Full Prescribing Information</a></li>
                <li class="headerMain-navUtilItem"><a class="headerMain-navUtilLink" href="#">Medication Guide</a></li>
                <li class="headerMain-navUtilItem"><a class="headerMain-navUtilLink" href="#">Indication</a></li>
                <li class="headerMain-navUtilItem"><a class="headerMain-navUtilLink" href="#">BLYINCYTO<sup>&reg;</sup>REMS</a></li>
              </ul>
              <ul class="headerMain-navUtilMobile">
                <li class="headerMain-navUtilMobileItem"><a class="headerMain-navUtilMobileLink" href="genericTemplate.html">Prescribing Info</a></li>
                <li class="headerMain-navUtilMobileItem"><a class="headerMain-navUtilMobileLink" href="genericTemplate.html">Indication</a></li>
              </ul>
            </div>
          </div>
          <div class="headerMain-main">
            <div class="headerMain-mainInner">
              <div class="headerMain-logo"><a class="headerMain-logoLink" href="home.html"><img class="headerMain-logoImg" src="img/content-images/logo-main.png"></a></div>
            </div>
          </div>
        </header>
        <main>
          <div class="hero profiles" style="background-image:url(img/content-images/patient-hero.png);">
            <div class="hero-inner">
              <div class="hero-copy"><span class="hero-zone">Patient Profiles</span></div>
            </div>
          </div>
          <section class="profile" id="roy">
            <div class="profile-header mb-md-0">
              <h2>First-line</h2>
            </div>
            <div class="profile-content">
              <div class="profile-content-left roy">
                <div class="profile-content-container upper" data-lg="img/content-images/roy-large.png" data-sm="img/content-images/roy.png">
                  <div class="overlay-content">
                    <div class="patient-info">
                      <div class="line"><span>Patient</span><span>Roy*</span></div>
                      <div class="line"><span>Gender</span><span>Male</span></div>
                      <div class="line"><span>Age</span><span>64</span></div>
                      <div class="line"><span>Occupation</span><span>Middle-school teacher</span></div>
                    </div>
                    <div class="qualifier"><span>*A hypothetical case study of a patient eligible for first-line mCRC therapy.</span></div>
                  </div>
                </div>
                <div class="profile-content-container roy placeholder"></div>
                <div class="profile-content-container orange"><img src="img/content-images/roy-scan.png">
                  <p class="reference colorWhite">ALT = alanine aminotransferase; AST = aspartate aminotransferase; CBC = complete blood count; CT = computed tomography; ECOG PS = Eastern Cooperative Oncology Group Performance Status; Hb = hemoglobin; mCRC = metastatic colorectal cancer; R0 resection = complete resection; WT = wild type. </p>
                </div>
              </div>
              <div class="profile-content-right roy">
                <div class="content">
                  <h3 class="mb-4">What clinical characteristics affect your first-line treatment decision?</h3>
                  <p class="lead">Medical history</p>
                  <ul>
                    <li>Mild hyperlipidemia, controlled on statin therapy</li>
                  </ul>
                  <p class="lead">Presentation</p>
                  <ul>
                    <li>3-month history of worsening constipation, bloating, and blood in stool</li>
                    <li>Colonoscopy confirmed 4 cm, nonobstructing mass in the left colon</li>
                  </ul>
                  <p class="lead">Pathology report</p>
                  <ul>
                    <li>Moderately differentiated adenocarcinoma</li>
                  </ul>
                  <p class="lead">Performance status</p>
                  <ul>
                    <li>ECOG PS = 1</li>
                  </ul>
                  <p class="lead">Laboratory results</p>
                  <ul>
                    <li>ALT: 70 U/L; AST: 180 U/L</li>
                    <li>CBC: Moderate anemia (Hb: 9.2 g/dL)</li>
                  </ul>
                  <p class="lead">Mutational status</p>
                  <ul>
                    <li>WT <em>RAS </em>(wild type in both <em>KRAS </em> and <em>NRAS)</em></li>
                  </ul>
                  <p class="lead">Imaging results</p>
                  <ul>
                    <li>CT scan indicated liver-limited metastases: 2 bilobar lesions (right: 3.5 cm; left: 6.5 cm)</li>
                  </ul>
                  <p class="lead">Surgery consult on metastatic disease</p>
                  <ul>
                    <li>Potentially resectable metastases, but not upfront R0 resection</li>
                    <li>Surgeon feels metastatic disease is potentially <span class="nowrap">resectable—treatment</span> goal is to downgrade the tumor</li>
                  </ul><a class="btn btn-secondary mt-4" href="">See first-line data</a>
                </div>
              </div>
            </div>
          </section>
          <section class="profile profile" id="brian">
            <div class="profile-header mb-md-0">
              <h2>First-line</h2>
            </div>
            <div class="profile-content">
              <div class="profile-content-left brian">
                <div class="profile-content-container upper" data-lg="img/content-images/brian-large.png" data-sm="img/content-images/brian.png">
                  <div class="overlay-content">
                    <div class="patient-info">
                      <div class="line"><span>Patient</span><span>Brian*</span></div>
                      <div class="line"><span>Gender</span><span>Male</span></div>
                      <div class="line"><span>Age</span><span>62</span></div>
                      <div class="line"><span>Occupation</span><span>Auto mechanic</span></div>
                    </div>
                    <div class="qualifier"><span>*A hypothetical case study of a patient eligible for first-line mCRC therapy.</span></div>
                  </div>
                </div>
                <div class="profile-content-container brian placeholder"></div>
                <div class="profile-content-container orange">
                  <div style="margin-bottom: 35px;"><img src="img/content-images/brian-scan.png" style="margin-bottom:0;">
                    <p class="reference colorWhite">Images are shown for illustrative purposes only</p>
                  </div>
                  <p class="reference colorWhite">ALT = alanine aminotransferase; AST = aspartate aminotransferase; CBC = complete blood count; CT = computed tomography; ECOG PS = Eastern Cooperative Oncology Group Performance Status; GERD = gastroesophageal reflux disease; Hb = hemoglobin; mCRC = metastatic colorectal cancer; WT = wild type. </p>
                </div>
              </div>
              <div class="profile-content-right brian">
                <div class="content">
                  <h3 class="mb-4">What clinical characteristics affect your first-line treatment decision?</h3>
                  <p class="lead">Medical history</p>
                  <ul>
                    <li>Mild GERD</li>
                  </ul>
                  <p class="lead">Presentation</p>
                  <ul>
                    <li>Sought medical treatment for frequent episodes of moderate/severe, right upper quadrant pain</li>
                    <li>Patient also complains of shortness of breath and pleuritic pain. Pain has noticeably worsened over the last month</li>
                    <li>Taking frequent pain medication</li>
                    <li>Colonoscopy indicated a 5 cm, nonobstructing mass in sigmoid colon</li>
                  </ul>
                  <p class="lead">Pathology report</p>
                  <ul>
                    <li>Moderately differentiated adenocarcinoma</li>
                  </ul>
                  <p class="lead">Performance status</p>
                  <ul>
                    <li>ECOG PS = 1</li>
                  </ul>
                  <p class="lead">Laboratory results</p>
                  <ul>
                    <li>ALT: 100 U/L; AST: 210 U/L</li>
                    <li>CBC: Mild/moderate anemia (Hb: 9.8 g/dL)</li>
                    <li>Bilirubin: 1.8 mg/dL</li>
                  </ul>
                  <p class="lead">Mutational status</p>
                  <ul>
                    <li>WT <em>RAS </em>(wild type in both <em>KRAS </em>and <em>NRAS</em>)</li>
                  </ul>
                  <p class="lead">Imaging results</p>
                  <ul>
                    <li>CT scan indicated diffuse, bulky metastatic involvement of lung and liver</li>
                  </ul>
                  <p class="lead">Surgery consult on metastatic disease</p>
                  <ul>
                    <li>Unresectable due to number of metastatic sites</li>
                  </ul><a class="btn btn-secondary mt-4" href="">See first-line data</a>
                </div>
              </div>
            </div>
          </section>
          <section class="profile" id="connie">
            <div class="profile-header mb-md-0">
              <h2>Third-line</h2>
            </div>
            <div class="profile-content pb-0">
              <div class="profile-content-left connie">
                <div class="profile-content-container tall upper" data-lg="img/content-images/connie-large.png" data-sm="img/content-images/connie.png">
                  <div class="overlay-content">
                    <div class="patient-info">
                      <div class="line"><span>Patient</span><span>Connie*</span></div>
                      <div class="line"><span>Gender</span><span>Female</span></div>
                      <div class="line"><span>Age</span><span>68</span></div>
                      <div class="line"><span>Occupation</span><span>Salesperson</span></div>
                    </div>
                    <div class="qualifier"><span>*A hypothetical case study of a patient eligible for third-line mCRC therapy.</span></div>
                  </div>
                  <div class="health-data connie">
                    <p class="reference colorWhite">ALT = alanine aminotransferase; AST = aspartate aminotransferase; CBC = complete blood count; CT = computed tomography; ECOG PS = Eastern Cooperative Oncology Group Performance Status; Hb = hemoglobin; mCRC = metastatic colorectal cancer; PLT = platelet; WBC = white blood cell count; WT = wild type. </p>
                  </div>
                </div>
                <div class="profile-content-container connie placeholder"></div>
              </div>
              <div class="profile-content-right connie">
                <div class="content">
                  <h3 class="mb-4">What clinical characteristics affect your third-line treatment decision?</h3>
                  <p class="lead">Medical history</p>
                  <ul>
                    <li>Osteoarthritis</li>
                  </ul>
                  <p class="lead">Presentation</p>
                  <ul>
                    <li>Initial presentation of mild abdominal discomfort and mild anemia</li>
                    <li>Colonoscopy revealed a nonobstructing mass in the left colon</li>
                    <li>CT scan revealed liver and lung metastases that were unresectable</li>
                  </ul>
                  <p class="lead">Prior therapy</p>
                  <ul>
                    <li>First-line treatment: FOLFOX + bevacizumab
                      <ul class="list-unstyled">
                        <li>&ndash; Progressed on therapy after 9 months</li>
                      </ul>
                    </li>
                    <li>Second-line treatment: FOLFIRI + bevacizumab
                      <ul class="list-unstyled">
                        <li>&ndash; Progressed on therapy after 7 months with liver and lung metastases</li>
                      </ul>
                    </li>
                  </ul>
                  <p class="lead">Performance status</p>
                  <ul>
                    <li>ECOG PS = 1</li>
                  </ul>
                  <p class="lead">Laboratory results</p>
                  <ul>
                    <li>ALT: 135 U/L; AST: 250 U/L</li>
                    <li>CBC
                      <ul class="list-unstyled">
                        <li>&ndash; WBC: 4.0 x 10<sup>3</sup> mL/µL</li>
                        <li>&ndash; Neutrophil: 1.6 x 10<sup>3</sup> mL/µL</li>
                        <li>&ndash; Hb: 9.0 g/dL</li>
                        <li>&ndash; PLT: 125 x 10<sup>3</sup> mL/µL</li>
                      </ul>
                    </li>
                    <li>Bilirubin: 1.8 mg/dL</li>
                  </ul>
                  <p class="lead">Mutational status</p>
                  <ul>
                    <li>WT <em>RAS </em>(wild type in both <em>KRAS </em>and <em>NRAS</em>)</li>
                  </ul>
                  <p class="lead">Imaging results</p>
                  <ul>
                    <li>CT scan indicated diffuse metastatic involvement of lung and liver</li>
                  </ul>
                  <p class="lead">Surgery consult on metastatic disease</p>
                  <ul>
                    <li>Unresectable due to number of metastatic sites</li>
                  </ul><a class="btn btn-secondary mt-4" href="">See third-line data</a>
                  <div class="health-data-placeholder connie"></div>
                </div>
              </div>
            </div>
          </section>
        </main>
        <div class="container">
          <div class="notifyTray is-sticky">
            <div class="notifyTray-inner">
              <div class="notifyTray-content">
                <div class="notifyTray-toggle"> 
                  <div class="notifyTray-toggleLink colorBrandBlue">See More</div>
                </div>
                <h3 class="colorBrandBlue">IMPORTANT SAFETY INFORMATION</h3>
                <p></p>
                <h4 class="h6 fontDefault">BOXED WARNING: DERMATOLOGIC TOXICITY</h4><strong>
                  <u>Dermatologic Toxicity:</u> Dermatologic toxicities occurred in 90% of patients and were severe (NCI-CTC grade 3 and higher) in 15% of patients receiving Vectibix
                   monotherapy </strong><em>[see Dosage and Administration (2.3), Warnings and Precautions (5.1), and Adverse Reactions (6.1)].</em>
                <p></p>
                <p></p>
                <ul>
                  <li>
                     In Study 20020408, dermatologic toxicities occurred in 90% of patients and were severe (NCI-CTC grade 3 and higher) in 15% of patients with mCRC receiving Vectibix<sup>&reg;</sup>. The clinical manifestations included, but were not limited to, acneiform dermatitis, pruritus, erythema, rash, skin exfoliation, paronychia, dry skin, and skin fissures.</li>
                  <li>
                     Monitor patients who develop dermatologic or soft tissue toxicities while receiving Vectibix<sup>&reg;</sup> for the development of inflammatory or infectious sequelae. Life-threatening and fatal infectious complications including necrotizing fasciitis, abscesses, and sepsis have been observed in patients treated with Vectibix<sup>&reg;</sup>. Life-threatening and fatal bullous mucocutaneous disease with blisters, erosions, and skin sloughing has also been observed in patients treated with Vectibix<sup>&reg;</sup>. It could not be determined whether these mucocutaneous adverse reactions were directly related to EGFR inhibition or to idiosyncratic immune-related effects (eg, Stevens Johnson syndrome or toxic epidermal necrolysis). Withhold or discontinue Vectibix<sup>&reg;</sup> for dermatologic or soft tissue toxicity associated with severe or life-threatening inflammatory or infectious complications. Dose modifications for Vectibix<sup>&reg;</sup> concerning dermatologic toxicity are provided in the product labeling.</li>
                  <li>
                     Vectibix<sup>&reg;</sup> is not indicated for the treatment of patients with colorectal cancer that harbor somatic <em> RAS</em> mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146) of either <em> KRAS</em> or <em> NRAS</em> and hereafter is referred to as "<em>RAS</em>."</li>
                  <li>
                     Retrospective subset analyses across several randomized clinical trials were conducted to investigate the role of <em> RAS</em> mutations on the clinical effects of anti-EGFR-directed monoclonal antibodies (panitumumab or cetuximab). Anti-EGFR antibodies in patients with tumors containing <em> RAS</em> mutations resulted in exposing those patients to anti-EGFR related adverse reactions without clinical benefit from these agents. Additionally, in Study 20050203, 272 patients with <em> RAS</em>-mutant mCRC tumors received Vectibix<sup>&reg;</sup> in combination with FOLFOX and 276 patients received FOLFOX alone. In an exploratory subgroup analysis, OS was shorter (HR = 1.21, 95% CI: 1.01-1.45) in patients with <em> RAS</em>-mutant mCRC who received Vectibix<sup>&reg;</sup> and FOLFOX versus FOLFOX alone.</li>
                  <li>
                     Progressively decreasing serum magnesium levels leading to severe (grade 3-4) hypomagnesemia occurred in up to 7% (in Study 20080763) of patients across clinical trials. Monitor patients for hypomagnesemia and hypocalcemia prior to initiating Vectibix<sup>&reg;</sup> treatment, periodically during Vectibix<sup>&reg;</sup> treatment, and for up to 8 weeks after the completion of treatment. Other electrolyte disturbances, including hypokalemia, have also been observed. Replete magnesium and other electrolytes as appropriate.</li>
                  <li>
                     In Study 20020408, 4% of patients experienced infusion reactions and 1% of patients experienced severe infusion reactions (NCI-CTC grade 3-4). Infusion reactions, manifesting as fever, chills, dyspnea, bronchospasm, and hypotension, can occur following Vectibix<sup>&reg;</sup> administration. Fatal infusion reactions occurred in postmarketing experience. Terminate the infusion for severe infusion reactions.</li>
                  <li>
                     Severe diarrhea and dehydration, leading to acute renal failure and other complications, have been observed in patients treated with Vectibix<sup>&reg;</sup> in combination with chemotherapy.</li>
                  <li>
                     Fatal and nonfatal cases of interstitial lung disease (ILD) (1%) and pulmonary fibrosis have been observed in patients treated with Vectibix<sup>&reg;</sup>. Pulmonary fibrosis occurred in less than 1% (2/1467) of patients enrolled in clinical studies of Vectibix<sup>&reg;</sup>. In the event of acute onset or worsening of pulmonary symptoms interrupt Vectibix<sup>&reg;</sup> therapy. Discontinue Vectibix<sup>&reg;</sup> therapy if ILD is confirmed.</li>
                  <li>
                     In patients with a history of interstitial pneumonitis or pulmonary fibrosis, or evidence of interstitial pneumonitis or pulmonary fibrosis, the benefits of therapy with Vectibix<sup>&reg;</sup> versus the risk of pulmonary complications must be carefully considered.</li>
                  <li>
                     Exposure to sunlight can exacerbate dermatologic toxicity. Advise patients to wear sunscreen and hats and limit sun exposure while receiving Vectibix<sup>&reg;</sup>.</li>
                  <li>
                     Keratitis and ulcerative keratitis, known risk factors for corneal perforation, have been reported with Vectibix<sup>&reg;</sup> use. Monitor for evidence of keratitis or ulcerative keratitis. Interrupt or discontinue Vectibix<sup>&reg;</sup> for acute or worsening keratitis.</li>
                  <li>
                     In an interim analysis of an open-label, multicenter, randomized clinical trial in the first-line setting in patients with mCRC, the addition of Vectibix<sup>&reg;</sup> to the combination of bevacizumab and chemotherapy resulted in decreased OS and increased incidence of NCI-CTC grade 3-5 (87% vs 72%) adverse reactions. NCI-CTC grade 3-4 adverse reactions occurring at a higher rate in Vectibix<sup>&reg;</sup>-treated patients included rash/acneiform dermatitis (26% vs 1%), diarrhea (23% vs 12%), dehydration (16% vs 5%), primarily occurring in patients with diarrhea, hypokalemia (10% vs 4%), stomatitis/mucositis (4% vs < 1%), and hypomagnesemia (4% vs 0).</li>
                  <li>
                     NCI-CTC grade 3-5 pulmonary embolism occurred at a higher rate in Vectibix<sup>&reg;</sup>-treated patients (7% vs 3%) and included fatal events in three (< 1%) Vectibix<sup>&reg;</sup>-treated patients. As a result of the toxicities experienced, patients randomized to Vectibix<sup>&reg;</sup>, bevacizumab, and chemotherapy received a lower mean relative dose intensity of each chemotherapeutic agent (oxaliplatin, irinotecan, bolus 5-FU, and/or infusional 5-FU) over the first 24 weeks on study compared with those randomized to bevacizumab and chemotherapy.</li>
                  <li>
                     Vectibix<sup>&reg;</sup> can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment, and for at least 2 months after the last dose of Vectibix<sup>&reg;</sup>.</li>
                  <li>
                     In monotherapy, the most commonly reported adverse reactions (≥ 20%) in patients with Vectibix<sup>&reg;</sup> were skin rash with variable presentations, paronychia, fatigue, nausea, and diarrhea.</li>
                  <li>
                     The most commonly reported adverse reactions (≥ 20%) with Vectibix<sup>&reg;</sup> + FOLFOX were diarrhea, stomatitis, mucosal inflammation, asthenia, paronychia, anorexia, hypomagnesemia, hypokalemia, rash, acneiform dermatitis, pruritus, and dry skin. The most common serious adverse reactions (≥ 2% difference between treatment arms) were diarrhea and dehydration. </li>
                </ul>
                <p>
                  Please see Vectibix
                   full <a href="http://pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/vectibix/vectibix_pi.ashx" target="_blank">Prescribing Information</a>, including <strong>Boxed WARNING</strong>.
                </p>
                <h3 class="colorBrandBlue" id="indication">Indication</h3>
                <p>Vectibix<sup>&reg; </sup> is indicated for the treatment of patients with wild‑type <em>RAS</em> (defined as wild‑type in both <em>KRAS</em> and <em>NRAS</em> as determined by an FDA‑approved test for this use) metastatic colorectal cancer (mCRC):</p>
                <ul>
                  <li>As first‑line therapy in combination with FOLFOX.</li>
                  <li>As monotherapy following disease progression after prior treatment with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑containing chemotherapy.</li>
                </ul>
                <h3 class="colorBrandBlue">Limitation of Use</h3>
                <p>Vectibix<sup>&reg; </sup> is not indicated for the treatment of patients with <em>RAS</em>‑mutant mCRC or for whom <em>RAS</em> mutation status is unknown.</p>
              </div>
            </div>
          </div>
        </div>
        <footer class="footerMain"><a class="footerMain-topLink" href="#pageTop">Back To Top<i class="footerMain-topLinkIcon fa-chevron-up"></i></a>
          <div class="footerMain-inner">
            <div class="footerMain-main">
              <ul class="footerMain-nav">
                <li class="footerMain-navItem"><a class="footerMain-navLink" href="site-map.html">Site Map</a></li>
                <li class="footerMain-navItem"><a class="footerMain-navLink" href="https://www.amgen.com/privacy-statement/">Privacy Statement</a></li>
                <li class="footerMain-navItem"><a class="footerMain-navLink" href="https://www.amgen.com/terms-of-use/">Terms of Use</a></li>
                <li class="footerMain-navItem"><a class="footerMain-navLink" href="http://www.amgenoncology.com/">Amgen Oncology</a></li>
                <li class="footerMain-navItem"><a class="footerMain-navLink" href="http://www.amgenassist360.com/hcp/vectibix-reimbursement-financial-assistance/">Amgen Assist 360<sup>TM</sup></a></li>
                <li class="footerMain-navItem"><a class="footerMain-navLink" href="https://www.amgenmedinfo.com/home">Amgen MedInfo</a></li>
                <li class="footerMain-navItem"><a class="footerMain-navLink" href="http://preferences-mgr.truste.com/?pid=amgen01&amp;aid=amgen_pub01&amp;type=amgen">Advertising Choices</a></li>
              </ul>
              <div class="footerMain-logo"> <a class="footerMain-logoLink" href="http://www.amgen.com/"><img class="footerMain-logoImg" src="img/content-images/logo-amgen.png"></a></div>
            </div>
            <div class="footerMain-collateral">
              <p>&copy; 2017 Amgen Inc. All rights reserved. USA-945-103094(5)</p>
              <p>This website is intended for US healthcare professionals only.</p>
            </div>
          </div>
        </footer>
      </div>
    </form>
  </body>
</html>